| 0.3686 -0.008 (-2.2%) | 04-24 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 0.65  |
1-year : | 0.79 |
| Resists | First : | 0.55 |
Second : | 0.68 |
| Pivot price | 0.42 |
|||
| Supports | First : | 0.36 |
Second : | 0.29 |
| MAs | MA(5) : | 0.4 |
MA(20) : | 0.43 |
| MA(100) : | 0.47 |
MA(250) : | 0.55 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 6  |
D(3) : | 9.6 |
| RSI | RSI(14): 34.7 |
|||
| 52-week | High : | 1.2 | Low : | 0.2 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ TOVX ] has closed below the lower bollinger band by 10.4%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ TOVX ] is to continue within current trading range. Bollinger Bands are 30% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.39 - 0.39 | 0.39 - 0.4 |
| Low: | 0.35 - 0.36 | 0.36 - 0.36 |
| Close: | 0.36 - 0.37 | 0.37 - 0.37 |
Theriva Biologics Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. It also develops VCN-01 for the treatment of patients with pancreatic cancer, head and neck squamous cell carcinoma, colorectal cancer, and retinoblastoma. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics; SYN-005 for the prevention and treatment of pertussis; and VCN-11 to treat cancer. It has collaborations with Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center; and a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. The company was formerly known as Synthetic Biologics, Inc. and changed its name to Theriva Biologics Inc. in October 2022. Theriva Biologics Inc. is headquartered in Rockville, Maryland.
Tue, 16 Apr 2024
Theriva Biologics Hits Several Milestones In 2023, Positioning Itself For Growth As The Firm Targets Diff - Benzinga
Mon, 08 Apr 2024
Theriva™ Biologics Announces Presentation at the American Society for Cell and Gene Therapy 27th Annual Meeting - GlobeNewswire
Tue, 26 Mar 2024
Theriva Biologics, Inc. (NYSE:TOVX) Q4 2023 Earnings Call Transcript - Yahoo Finance
Mon, 25 Mar 2024
Theriva™ Biologics Reports Full-Year 2023 Operational Highlights and Financial Results - GlobeNewswire
Mon, 25 Mar 2024
Theriva Biologics, Inc. (TOVX) Q4 2023 Earnings Call Transcript - Seeking Alpha
Fri, 22 Mar 2024
Preview: Theriva Biologics's Earnings - Theriva Biologics (AMEX:TOVX) - Benzinga
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 17 (M) |
| Shares Float | 17 (M) |
| Held by Insiders | 1.9 (%) |
| Held by Institutions | 6.2 (%) |
| Shares Short | 385 (K) |
| Shares Short P.Month | 413 (K) |
| EPS | -1.25 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.41 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -21.2 % |
| Return on Equity (ttm) | -37.9 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.39 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -18 (M) |
| Levered Free Cash Flow | -21 (M) |
| PE Ratio | -0.3 |
| PEG Ratio | 0 |
| Price to Book value | 0.15 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.36 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|